Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells

BMC Pharmacology

Volumn 11, Issue , 2011, Pages

  Alli, Elizabeth ^a   Sharma, Vandana B ^a   Hartman, Anne Renee ^a   Lin, Patrick S ^a   McPherson, Lisa ^a   Ford, James M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MESSENGER RNA; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; DRUG SENSITIVITY; EPITHELIUM CELL; GENE MUTATION; GENETIC ASSOCIATION; IC 50; MOUSE; MURINE MAMMARY EPITHELIAL CELL; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; UDDER;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; EPITHELIAL CELLS; FEMALE; GENES, BRCA1; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE;

EID: 79960565400     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-11-7     Document Type: Article

References (71)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130. 10.1086/375033, 1180265, 12677558.
2. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006, 8(4):R38. 10.1186/bcr1522, 1779478, 16846527.
3. Butcher DT, Rodenhiser DI. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. European journal of cancer 2007, 43(1):210-219. 10.1016/j.ejca.2006.09.002, 17071074.
4. Catteau A, Morris JR. BRCA1 methylation: a significant role in tumour development?. Semin Cancer Biol 2002, 12(5):359-371. 10.1016/S1044-579X(02)00056-1, 12191635.
5. Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T, Ushijima T. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 2002, 32(3):79-84. 10.1093/jjco/hyf020, 11956301.
6. Rice JC, Futscher BW. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic acids research 2000, 28(17):3233-3239. 10.1093/nar/28.17.3233, 110706, 10954590.
7. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature genetics 1999, 21(2):236-240. 10.1038/6029, 9988281.
8. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20(9):2310-2318. 10.1200/JCO.2002.09.023, 11981002.
9. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005, 90(1):5-14. 10.1007/s10549-004-1536-0, 15770521.
10. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244. 10.1016/S0140-6736(10)60892-6, 20609467.
11. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005, 3(10):531-539. 10.1158/1541-7786.MCR-05-0192, 16254187.
12. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009, 69(8):3589-3596. 10.1158/0008-5472.CAN-08-4016, 2681413, 19351835.
13. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002, 32(1):180-184. 10.1038/ng953, 12195423.
14. Hartman AR, Ford JM. BRCA1 and p53: compensatory roles in DNA repair. J Mol Med 2003, 81(11):700-707. 10.1007/s00109-003-0477-0, 13679996.
15. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275(31):23899-23903. 10.1074/jbc.C000276200, 10843985.
16. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97(9):2187-2195. 10.1002/cncr.11310, 12712470.
17. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998, 58(6):1120-1123.
18. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63(19):6221-6228.
19. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002, 20(4):845-853.
20. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003, 88(8):1285-1291. 10.1038/sj.bjc.6600859, 2747554, 12698198.
21. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917. 10.1038/nature03443, 15829966.
22. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921. 10.1038/nature03445, 15829967.
23. Sgagias MK, Wagner KU, Hamik B, Stoeger S, Spieker R, Huber LJ, Chodosh LA, Cowan KH. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004, 3(11):1451-1456. 10.4161/cc.3.11.1211, 15492509.
24. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22(1):37-43. 10.1038/8743, 10319859.
25. Lin PS, McPherson LA, Chen AY, Sage J, Ford JM. The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA Repair (Amst) 2009, 8(7):795-802.
26. Fitch ME, Cross IV, Turner SJ, Adimoolam S, Lin CX, Williams KG, Ford JM. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair (Amst) 2003, 2(7):819-826.
27. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 1995, 92(19):8876-8880. 10.1073/pnas.92.19.8876, 41070, 7568035.
28. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace AJ. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol 2000, 20(10):3705-3714. 10.1128/MCB.20.10.3705-3714.2000, 85670, 10779360.
29. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001, 298(3):865-872.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
31. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175(1):184-191. 10.1016/0014-4827(88)90265-0, 3345800.
32. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998, 17(13):1681-1689. 10.1038/sj.onc.1202106, 9796697.
33. Schuyer M, Berns EM. Is TP53 dysfunction required for BRCA1-associated carcinogenesis?. Mol Cell Endocrinol 1999, 155(1-2):143-152. 10.1016/S0303-7207(99)00117-3, 10580847.
34. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999, 3(3):389-395. 10.1016/S1097-2765(00)80466-9, 10198641.
35. Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther 2002, 1(2):177-186.
36. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001, 291(5507):1284-1289. 10.1126/science.1056154, 11181991.
37. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 2006, 84(1):16-28. 10.1007/s00109-005-0696-7, 16283147.
38. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 1999, 84(3):258-262. 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H, 10371343.
39. Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000, 18(24):4045-4052.
40. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelenat H, Pouillart P, Vincent-Salomon A, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000, 18(24):4053-4059.
41. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006, 5(2):135-142. 10.1007/s10689-005-2832-5, 16736282.
42. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4(9):665-676. 10.1038/nrc1431, 15343273.
43. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006, 34(Pt 5):633-645.
44. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010, 11(2):138-148. 10.1038/nrm2831, 20029420.
45. Gramatges MM, Telli ML, Balise R, Ford JM. Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol Biomarkers Prev 2010, 19(2):605-613. 10.1158/1055-9965.EPI-09-0896, 20142254.
46. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP, Elledge SJ. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316(5828):1194-1198. 10.1126/science.1139476, 17525340.
47. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007, 28(5):739-745. 10.1016/j.molcel.2007.11.015, 18082599.
48. Wang B, Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA 2007, 104(52):20759-20763. 10.1073/pnas.0710061104, 2410075, 18077395.
49. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010, 70(20):7970-7980. 10.1158/0008-5472.CAN-09-4521, 20798217.
50. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478(1-2):23-43.
51. Crul M, Schellens JH, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997, 23(5-6):341-366. 10.1016/S0305-7372(97)90032-3, 9465884.
52. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007, 67(15):7078-7081. 10.1158/0008-5472.CAN-07-0601, 17671173.
53. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010, 19(3):246-248. 10.1016/j.breast.2010.02.003, 20227277.
54. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007, 6(4):1239-1248. 10.1158/1535-7163.MCT-06-0633, 17406032.
55. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 2006, 281(12):7834-7841. 10.1074/jbc.M512894200, 16436374.
56. Niida H, Katsuno Y, Sengoku M, Shimada M, Yukawa M, Ikura M, Ikura T, Kohno K, Shima H, Suzuki H, et al. Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase. Genes Dev 2010, 24(4):333-338. 10.1101/gad.1863810, 2816732, 20159953.
57. De Ligio JT, Velkova A, Zorio DA, Monteiro AN. Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?. Anticancer Agents Med Chem 2009, 9(5):543-549. 2745270, 19519295.
58. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96(22):1659-1668. 10.1093/jnci/djh312, 15547178.
59. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006, 66(18):8949-8953. 10.1158/0008-5472.CAN-06-1495, 1802660, 16982732.
60. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996, 2(3):521-530.
61. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003, 63(4):862-869. 10.1124/mol.63.4.862, 12644587.
62. Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998, 12(4):825-832.
63. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999, 80(7):981-990. 10.1038/sj.bjc.6690452, 2363050, 10362105.
64. Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I. DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 2009, 9:359. 10.1186/1471-2407-9-359, 2768745, 19818145.
65. Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, Schellens JH. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003, 65(2):275-282. 10.1016/S0006-2952(02)01508-3, 12504803.
66. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 2006, 28(1):237-244.
67. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000, 6(3):773-781.
68. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clinical cancer research an official journal of the American Association for Cancer Research 2010, 16(1):99-108.
69. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28(3):375-379. 10.1200/JCO.2008.20.7019, 20008645.
70. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28(7):1145-1153. 10.1200/JCO.2009.22.4725, 2834466, 20100965.
71. Telli ML, Ford JM. Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer 2010, 10(Suppl 1):E16-22.